| 30th Oct 2026 4:30 pm |
MFN |
BioInvent International: Supplement: Notice to Extraordinary General Meeting in BioInvent International AB |
| 28th Oct 2026 5:17 pm |
MFN |
BioInvent International: BioInvent International AB: Interim report January – September, 2026 |
| 28th Oct 2026 5:16 pm |
MFN |
BioInvent International: Notice to Extraordinary General Meeting in BioInvent International AB |
| 28th Oct 2026 5:15 pm |
MFN |
BioInvent International: BioInvent resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January – September 2026 |
| 24th Oct 2026 8:00 am |
MFN |
BioInvent International: BioInvent's BI-1808 and KEYTRUDA® Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer |
| 12th Oct 2026 8:45 am |
MFN |
BioInvent International: BioInvent International AB announces that its CFO will retire in 2027 |
| 27th Aug 2026 7:00 am |
MFN |
BioInvent International: BioInvent International AB: Interim report January - June 2026 |
| 21st May 2026 10:00 pm |
MFN |
BioInvent International: BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA® (pembrolizumab) in Advanced Ovarian Cancer at ASCO |
| 29th Apr 2026 3:30 pm |
MFN |
BioInvent International: Resolutions at BioInvent’s Annual General Meeting 2026 |
| 29th Apr 2026 6:00 am |
MFN |
BioInvent International: BioInvent International AB: Interim report January - March 2026 |
| 31st Mar 2026 9:45 am |
MFN |
BioInvent International AB publishes Annual Report 2025 |
| 24th Mar 2026 7:00 am |
MFN |
Notice to Annual General Meeting in BioInvent International AB |
| 26th Feb 2026 7:00 am |
MFN |
BioInvent International AB: Year-end report January 1 - December 31, 2025 |
| 5th Jan 2026 6:30 am |
MFN |
BioInvent Reports Promising Data from Ongoing Phase 2a study for BI-1808 with KEYTRUDA® (pembrolizumab) in Recurrent Ovarian Cancer |
| 8th Dec 2025 1:00 pm |
MFN |
BioInvent Presents Impressive Response Data from Ongoing Phase 2a Trial of Triple Combination BI-1206, Rituximab, and Calquence in r/r NHL at ASH 2025 |
| 7th Dec 2025 1:00 pm |
MFN |
BioInvent Presents Promising Early Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025 |
